| Lu, Hongzhou |
| Completed | 3 | 1369 | RoW | JT001, VV116, Placebo | Shanghai Vinnerna Biosciences Co., Ltd., Sponsor GmbH | Mild to Moderate COVID-19 | 02/23 | 02/23 | | |
NCT05716425: Study to Assess the Efficacy and Safety of STI-1558 in Adult Subjects With Mild or Moderate (COVID-19) |
|
|
| Completed | 3 | 1218 | RoW | STI-1558, STI-1558 placebo | Zhejiang ACEA Pharmaceutical Co. Ltd. | COVID-19 | 07/23 | 07/23 | | |
NCT05113784: the Safety and Efficacy of Meplazumab in Patients With COVID-19 |
|
|
| Completed | 2/3 | 150 | RoW | Meplazumab for Injection, Sterile normal saline (0.9%) | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | Covid19 | 09/22 | 10/22 | | |
NCT05675072: Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19 |
|
|
| Recruiting | 2/3 | 1336 | RoW | FB2001, FB2001 for Inhalation, FB2001 placebo, placebo | Frontier Biotechnologies Inc. | Mild to Moderate COVID-19 | 09/23 | 12/23 | | |
NCT05676073: Study of SHEN26 Capsule in Patients With Mild to Moderate COVID-19 |
|
|
| Completed | 2 | 91 | RoW | SHEN26 dose 1, SHEN26 dose 2, SHEN26 placebo | Shenzhen Kexing Pharmaceutical Co., Ltd. | COVID-19 | 12/22 | 01/23 | | |
NCT05702788: Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19) |
|
|
| Withdrawn | 2 | 168 | NA | Jaktinib hydrochloride tablets, Placebo | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | COVID-19, Pneumonia | 04/24 | 04/24 | | |
NCT06288893: Phase II Clinical Study of SHEN211 Tablets in the Treatment of Mild and Moderate Novel Corona Virus Infection (COVID-19) |
|
|
| Not yet recruiting | 2 | 30 | RoW | SHEN211 Tablets, Test group, Placebo for SHEN211 Tablets, control group | JKT Biopharma Co., Ltd. | COVID-19 | 08/24 | 01/25 | | |
NCT05369676: To Evaluate SSD8432/ Ritonavir in Adults With COVID-19 |
|
|
| Completed | 1/2 | 32 | RoW | SSD8432 dose 1/Ritonavir, SIM0417 dose 1/Ritonavir, SSD8432 dose 2/Ritonavir, SIM0417 dose 2/Ritonavir | Jiangsu Simcere Pharmaceutical Co., Ltd. | COVID-19 Patients | 08/22 | 08/22 | | |
| Not yet recruiting | 1 | 12 | RoW | Euphorbia kansui Pill, kansui | Shanghai Public Health Clinical Center, Fudan University, Shanghai Xinhao Biological Technology Co., Ltd. | HIV-1-infection | 08/22 | 12/22 | | |
NCT05523739: Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients |
|
|
| Completed | 1 | 79 | RoW | STI-1558 | Zhejiang ACEA Pharmaceutical Co. Ltd. | SARS-CoV-2 Infection | 12/22 | 03/23 | | |
| Active, not recruiting | 1 | 45 | RoW | ICVAX, Placebo | Immuno Cure Holding (HK) Limited, Shenzhen Third People's Hospital, Shenzhen Immuno Cure Biomedical Company Limited | Human Immunodeficiency Virus, Human Immunodeficiency Virus I Infection | 09/24 | 01/25 | | |
NCT05038449: Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 |
|
|
| Not yet recruiting | N/A | 60 | RoW | Colchicine Tablets, Standard therapy | Shanghai Public Health Clinical Center, Kunming Pharmaceuticals, Inc. | Covid19, Colchicine | 06/23 | 09/23 | | |
NCT06560840: Effectiveness of Gut Microbiota-targeted Diatery Intervention Among Older People Living With HIV |
|
|
| Recruiting | N/A | 110 | RoW | dietary intervention | Fudan University | Hiv, Atherosclerosis, Diet, Healthy | 05/25 | 05/25 | | |
| Yuan, Jing |
| Active, not recruiting | 3 | 871 | Europe, Canada, Japan, US, RoW | Bepirovirsen, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Chronic Hepatitis B, Hepatitis B, Chronic | 11/25 | 05/26 | | |
| Liu, Yingxia |
NCT03476083: Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission |
|
|
| Recruiting | 4 | 280 | RoW | Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily., HBIg 200 IU im for infants in the group B, HBV vaccine 10 ug im for all infants | New Discovery LLC | Hepatitis B Infection, Congenital Malformation, Birth Defect, Viremia, Chronic Infection | 05/21 | 05/24 | | |
NCT05113784: the Safety and Efficacy of Meplazumab in Patients With COVID-19 |
|
|
| Completed | 2/3 | 150 | RoW | Meplazumab for Injection, Sterile normal saline (0.9%) | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | Covid19 | 09/22 | 10/22 | | |
| Recruiting | N/A | 50000 | RoW | comprehensive management algorithm for preventing mother-to-child transmission of HBV | Nanfang Hospital of Southern Medical University, Chinese Foundation for Hepatitis Prevention and Control, Tigermed Consulting Co., Ltd | Hepatitis B, Chronic, Mother to Child Transmission | 06/25 | 12/25 | | |
| Lu, Shuihua |
NCT05899179: Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above |
|
|
| Recruiting | 3 | 780 | RoW | Recombinant Mycobacterium Tuberculosis Fusion Protein, EC, Purified Protein Derivative of Tuberculin, TB-PPD | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Shenzhen Third People's Hospital, Wuhan Institute for Tuberculosis Control | Latent Tuberculosis Infection | 06/25 | 10/25 | | |
NCT04538911: Phase I Clinical Protocol for Pre-evaluation of the Safety of BCG-PPD in Tuberculosis Patients |
|
|
| Active, not recruiting | 1 | 60 | RoW | BCG-PPD | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Shenzhen Third People's Hospital, Beijing Kangterike Statistical Technology Co., Ltd., Wuhan Pulmonary Hospital | Tuberculosis | 05/23 | 12/25 | | |
NCT06525272: A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of OsrhCT in Patients With Pleurisy |
|
|
| Not yet recruiting | 1 | 72 | RoW | Recombinant Human Chymotrypsin(OsrhCT), Freeze-dried Powder of Recombinant Human Chymotrypsin(OsrhCT), Placebo for Recombinant Human Chymotrypsin(OsrhCT), Freeze-dried Powder of Placebo for Recombinant Human Chymotrypsin(OsrhCT) | Healthgen Biotechnology Corp. | Pleurisy | 07/25 | 12/25 | | |
| Li, Guojun |
NCT05632861: HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR) |
|
|
| Recruiting | 2 | 76 | RoW | HuHuangLianzonggan capsule, Experimental group, HuHuangLianzonggan capsule placebo, Placebo group | Tasly Pharmaceutical Group Co., Ltd | NASH | 12/24 | 12/24 | | |
| Yang, Liuqing |
NCT03476083: Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission |
|
|
| Recruiting | 4 | 280 | RoW | Tenofovir Disoproxil Fumarate (TDF) 300 mg oral daily., HBIg 200 IU im for infants in the group B, HBV vaccine 10 ug im for all infants | New Discovery LLC | Hepatitis B Infection, Congenital Malformation, Birth Defect, Viremia, Chronic Infection | 05/21 | 05/24 | | |
| Huang, Hai |
NCT05580354: Safety and Efficacy of BCG Combined With Tislelizumab for BCG-untreated Patients With High-risk Non-muscle Invasive Bladder Cancer |
|
|
| Not yet recruiting | 4 | 42 | RoW | BCG combined with Tislelizumab | Ruijin Hospital | Non-muscle-invasive Bladder Cancer | 10/24 | 05/25 | | |
PINES, NCT03939637: Eltrombopag Vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children |
|
|
| Active, not recruiting | 3 | 122 | US | Eltrombopag, Steroids, IVIG, Rho(D) Immune Globulin | Baylor College of Medicine, Boston Children's Hospital, University of California, San Francisco | Immune Thrombocytopenia | 03/25 | 12/25 | | |
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer |
|
|
| Active, not recruiting | 3 | 496 | Europe, US, RoW | Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 12/26 | 12/26 | | |
NCT05633589: A Clinical Study to Evaluate Safety, Tolerance, Pharmacokinetics and Efficacy of Sc610 Injection for Treating Advanced Urinary System Tumors |
|
|
| Not yet recruiting | 1/2 | 45 | NA | Sc610 cell injection | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Malignant Tumor of Urinary System (Disorder) | 05/24 | 10/24 | | |
NCT04676035: The DDI Study Had Been Designed to Investigate the Effect of SHR3680 on the Pharmacokinetics of Midazolam, S-Warfarin and Omeprazole |
|
|
| Completed | 1 | 18 | RoW | Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680 | Jiangsu HengRui Medicine Co., Ltd. | Prostate Cancer Patients | 01/22 | 01/22 | | |
NCT04538911: Phase I Clinical Protocol for Pre-evaluation of the Safety of BCG-PPD in Tuberculosis Patients |
|
|
| Active, not recruiting | 1 | 60 | RoW | BCG-PPD | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Shenzhen Third People's Hospital, Beijing Kangterike Statistical Technology Co., Ltd., Wuhan Pulmonary Hospital | Tuberculosis | 05/23 | 12/25 | | |
NCT04928612: A Study of CBP-1018 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 170 | RoW | CBP-1018 | Coherent Biopharma (Suzhou) Co., Ltd. | Solid Tumor | 10/24 | 12/24 | | |
NCT05638269: A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China |
|
|
| Recruiting | N/A | 12000 | RoW | no intervention | Zhujiang Hospital, National Natural Science Foundation of China | Essential Hypertension, Liver Cancer, Nasopharyngeal Cancer, Pancreatic Cancer, Lung Cancer, Chronic Kidney Diseases, Acute Coronary Syndrome, Epilepsy, Gastric Cancer, Primary Aldosteronism, Subclinical hypothyroïdism | 12/24 | 12/25 | | |
| Qu, Jiuxin |
NCT04694495: HPV Infection and Genital Microecology of Childbearing-age Female in China: A Cohort and Multicenter Study |
|
|
| Recruiting | N/A | 10000 | RoW | 16S rRNA gene sequencing of cervical secretions, Microecology assessment of cervical secretions, Genotyping of HPV and detection of sexually transmitted diseases pathogens, Thinprep cytologic test of cervical exfoliated cells | Zhujiang Hospital, Peking University First Hospital, The Affiliated Hospital Of Guizhou Medical University, Hainan General Hospital, LanZhou University, Lianyungang Hospital Affiliated Bengbu Medical College, General Hospital of Ningxia Medical University, Jinan Central Hospital, Tibet Autonomous Region People's Hospital, The Affiliated Hospital Of Southwest Medical University, Anhui Provincial Hospital, The First People's Hospital of Zunyi, The Third Affiliated Hospital of Southern Medical University, First Affiliated Hospital, Sun Yat-Sen University, Zhuhai Center for Maternal and Child Health Care, First Affiliated Hospital of Guangxi Medical University, Qinghai Red Cross Hospital, Changzhi People's Hospital, Shanghai East Hospital, Fifth Affiliated Hospital of Guangzhou Medical University, Huizhou Municipal Central Hospital, Nanfang Hospital, Southern Medical University, Yuebei People's Hospital, The Seventh Affiliated Hospital of Sun Yat-sen University, Fujian Maternity and Child Health Hospital, The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine, Henan Provincial People's Hospital, The Fifth Affiliated Hospital of Southern Medical University, Shandong Provincial Hospital, First Hospital of China Medical University, Gansu Provincial Hospital | Papillomavirus Infections, Uterine Cervical Neoplasms, Sexual Transmitted Disease | 12/24 | 12/24 | | |
| Wang, Zhongyuan |
NCT04538911: Phase I Clinical Protocol for Pre-evaluation of the Safety of BCG-PPD in Tuberculosis Patients |
|
|
| Active, not recruiting | 1 | 60 | RoW | BCG-PPD | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Shenzhen Third People's Hospital, Beijing Kangterike Statistical Technology Co., Ltd., Wuhan Pulmonary Hospital | Tuberculosis | 05/23 | 12/25 | | |
| Liu, Guan |
NCT04538911: Phase I Clinical Protocol for Pre-evaluation of the Safety of BCG-PPD in Tuberculosis Patients |
|
|
| Active, not recruiting | 1 | 60 | RoW | BCG-PPD | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Shenzhen Third People's Hospital, Beijing Kangterike Statistical Technology Co., Ltd., Wuhan Pulmonary Hospital | Tuberculosis | 05/23 | 12/25 | | |
NCT06525272: A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of OsrhCT in Patients With Pleurisy |
|
|
| Not yet recruiting | 1 | 72 | RoW | Recombinant Human Chymotrypsin(OsrhCT), Freeze-dried Powder of Recombinant Human Chymotrypsin(OsrhCT), Placebo for Recombinant Human Chymotrypsin(OsrhCT), Freeze-dried Powder of Placebo for Recombinant Human Chymotrypsin(OsrhCT) | Healthgen Biotechnology Corp. | Pleurisy | 07/25 | 12/25 | | |
| Deng, Xuesong |
NCT03598465: Evaluating the Association Between Sphingolipid Metabolites and Post-hepatectomy Liver Failure |
|
|
| Completed | N/A | 591 | RoW | | Nanfang Hospital, Southern Medical University | Post-hepatectomy Liver Failure | 09/24 | 10/24 | | |
| Yu, Junwen |
NCT06279819: Effectiveness of Gut Microbiota-targeted Dietary Intervention Among HIV-infected Patients |
|
|
| Not yet recruiting | N/A | 106 | RoW | gut microbiota-targeted dietary intervention | Fudan University | Hiv, Cardiovascular Diseases, Diet, Healthy | 12/24 | 12/24 | | |
NCT06560840: Effectiveness of Gut Microbiota-targeted Diatery Intervention Among Older People Living With HIV |
|
|
| Recruiting | N/A | 110 | RoW | dietary intervention | Fudan University | Hiv, Atherosclerosis, Diet, Healthy | 05/25 | 05/25 | | |
